Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

NEW YORK (Reuters) - About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Old Town Med Spa is among those being accused of using false advertising and deceptive marketing practices to sell ...

The only approved oral GLP-1 drug is Rybelsus, a pill for type 2 diabetes from Novo Nordisk, the same company that makes ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.

Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...